Health Care Innovation
Commentary
Let’s talk about medical debt
A federal judge this month tossed out a Biden-era rule that would have wiped medical debt from consumers’ credit reports. The decision is a victory for borrowers and lenders alike. The now-defunct rule could have ended up hurting the very low-income individuals it was meant to help. Read the entire ...
Blog
The U.S. Drug System Strikes a Reasonable Balance Between Incentivizing Innovation and Promoting Competition
The government explicitly grants innovators temporary market exclusivity to provide an opportunity for groundbreaking pharmaceutical companies to recover the costs of capital associated with developing novel treatments. This was one of the express purposes of past federal reform legislation, such as the Hatch-Waxman Act signed in 1984 and the Biologics ...
Commentary
Trump Must Shut Down Counterfeit Weight-Loss Drugs
Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Commentary
Private Efforts Not Public Committees Will Generate Healthcare Savings
Passed as part of the Affordable Care Act (ACA), the Center for Medicare & Medicaid Innovation (CMMI) was allocated $10 billion in 2011 for the first decade of its existence. It has been allocated hundreds of millions more since. The purpose of the program is to create payment models that ...
Drug Importation
Listen to Sally Pipes on “Free the Economy” podcast
Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Blog
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Commentary
President Trump Hasn’t Given Up on Hospital Price Transparency
For markets to function efficiently, consumers need to know how much things cost. This is as true for eggs and milk as it is for medical care. And it was this very insight that motivated the rule that President Donald J. Trump implemented during his first term in 2019 ordering ...
Commentary
Is Era of Biomedical Innovation Wins Against Cancer Over?
For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
Commentary
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Let’s talk about medical debt
A federal judge this month tossed out a Biden-era rule that would have wiped medical debt from consumers’ credit reports. The decision is a victory for borrowers and lenders alike. The now-defunct rule could have ended up hurting the very low-income individuals it was meant to help. Read the entire ...
The U.S. Drug System Strikes a Reasonable Balance Between Incentivizing Innovation and Promoting Competition
The government explicitly grants innovators temporary market exclusivity to provide an opportunity for groundbreaking pharmaceutical companies to recover the costs of capital associated with developing novel treatments. This was one of the express purposes of past federal reform legislation, such as the Hatch-Waxman Act signed in 1984 and the Biologics ...
Trump Must Shut Down Counterfeit Weight-Loss Drugs
Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Private Efforts Not Public Committees Will Generate Healthcare Savings
Passed as part of the Affordable Care Act (ACA), the Center for Medicare & Medicaid Innovation (CMMI) was allocated $10 billion in 2011 for the first decade of its existence. It has been allocated hundreds of millions more since. The purpose of the program is to create payment models that ...
Listen to Sally Pipes on “Free the Economy” podcast
Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
President Trump Hasn’t Given Up on Hospital Price Transparency
For markets to function efficiently, consumers need to know how much things cost. This is as true for eggs and milk as it is for medical care. And it was this very insight that motivated the rule that President Donald J. Trump implemented during his first term in 2019 ordering ...
Is Era of Biomedical Innovation Wins Against Cancer Over?
For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
